Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
INDIAN WELLS, Calif., April 06, 2018 -- Nova Oculus Partners, LLC today issued the following statement from its founder Peter Pocklington:
I am extremely proud of what we have accomplished in a short time.
I founded Nova Oculus four years ago because I firmly believe the microcurrent electro-therapy technology behind our medical device successfully mitigates symptoms of the dry version of Age-Related Macular Degeneration.
I personally suffer from AMD, and my experience with early prototypes of our device attests to its promise. And I’m not the only one.
We have a blue-ribbon team of professionals leading our efforts to bring Nova Oculus to market. We also assembled a medical advisory board that includes some of the leading optometric professionals in the United States to develop a plan to earn FDA approval and widespread commercialization in the U.S.
Our device is currently being considered for a medical license by the Canadian government regulator, Health Canada, for commercialization in that country. It also is undergoing a clinical trial with patient test groups in Calgary, Canada.
Our Nova Oculus device has been certified by the International Organization of Standardization (ISO) as complying with quality control and safety in its development, and by the International Electrotechnical Commission, which gave its approval for the device’s electrical safety. These certifications pave the way for global regulatory approvals for Nova Oculus.
The real story of Nova Oculus is our promising technology, our brilliant team and our achievements. This created credibility for the company and faith by investors.
The SEC’s announcement was a laundry list of misguided accusations based on unrelated items of dubious interest. We intend to vigorously defend our reputation. We will fight to bring the Nova Oculus medical device to market. It’s the right thing to do.
AMD has no cure. It is the leading cause of blindness in North America. More than 14 million people suffer from this affliction — a figure that is expected to double as baby boomers age.
Our goal is unwavering. We will do all we can to restore sight to people who would otherwise not have any.
That is my promise to you.
Peter Pocklington
Founder, Nova Oculus
Contact:
Sonya Bucher
[email protected]
(323) 399-1166
